Begin main content

CADTH pan-Canadian Oncology Drug Review

pCODR RSS feed

The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.

The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.

Drug Review Updates

Pembrolizumab (Keytruda) for Melanoma Adjuvant Treatment
(Notification to Implement Issued as of August 19, 2019)

Lutetium Lu 177 dotatate (Lutathera) for Gastroenteropancreatic Neuroendocrine Tumors
(Notification to Implement Issued as of August 19, 2019)

Brigatinib (Alunbrig) for Non-Small Cell Lung Cancer
(Notification to Implement Issued as of August 19, 2019)

Lenvatinib (Lenvima) for Hepatocellular Carcinoma
(Notification to Implement Issued as of August 9, 2019)

Midostaurin (Rydapt) for Systemic Mastocytosis
(Open for Input on Submission until August 27, 2019)

Gemtuzumab Ozogamicin (Brand Name: TBD) for Acute Myeloid Leukemia
(Open for Input on Submission until August 23, 2019)

Pembrolizumab (Keytruda) for Renal Cell Carcinoma
(Open for Input on Submission until August 19, 2019)

Trifluridine-Tipiracil (Lonsurf) for Gastric Cancer
(Pending Submission as of August 2, 2019)

Darolutamide (Brand Name: TBD) for Non-Metastatic Castration Resistant Prostate Cancer
(Pending Submission as of July 26, 2019)

Ribociclib (Kisqali) with Fulvestrant for Advanced or Metastatic Breast Cancer
(Pending Submission as of July 26, 2019)

Ribociclib (Kisqali) for Advanced or Metastatic Breast Cancer
(Pending Submission as of July 26, 2019)

Find a Drug Review